Abstract

Human chymase is a very important target for the treatment of cardiovascular diseases. Using a series of theoretical methods like pharmacophore modeling, database screening, molecular docking and Density Functional Theory (DFT) calculations, an investigation for identification of novel chymase inhibitors, and to specify the key factors crucial for the binding and interaction between chymase and inhibitors is performed. A highly correlating (r = 0.942) pharmacophore model (Hypo1) with two hydrogen bond acceptors, and three hydrophobic aromatic features is generated. After successfully validating “Hypo1”, it is further applied in database screening. Hit compounds are subjected to various drug-like filtrations and molecular docking studies. Finally, three structurally diverse compounds with high GOLD fitness scores and interactions with key active site amino acids are identified as potent chymase hits. Moreover, DFT study is performed which confirms very clear trends between electronic properties and inhibitory activity (IC50) data thus successfully validating “Hypo1” by DFT method. Therefore, this research exertion can be helpful in the development of new potent hits for chymase. In addition, the combinational use of docking, orbital energies and molecular electrostatic potential analysis is also demonstrated as a good endeavor to gain an insight into the interaction between chymase and inhibitors.

Highlights

  • Raised blood pressure, especially systolic pressure, is one of the striking factors inducing various diseases like heart failure, stroke, myocardial infarction and arterial aneurysm, and is a leading cause of chronic kidney failure [1]

  • The subject of the present study is to develop quantitative structure-activity relationship (QSAR) models and explore the key molecular features of chymase inhibitors influencing the protein-ligand binding and interaction, by exploring the dependence of inhibitory activities upon various physiochemical properties of these compounds

  • The total cost values of all randomized models and root mean square deviations (RMSDs) values were higher than Hypo1, which is not appropriate for a good pharmacophore model

Read more

Summary

Introduction

Especially systolic pressure (hypertension), is one of the striking factors inducing various diseases like heart failure, stroke, myocardial infarction and arterial aneurysm, and is a leading cause of chronic kidney failure [1]. Conversion of angiotensin I (Ang I) to angiotensin II (Ang II) is catalyzed by well-known angiotensin-converting enzyme (ACE), which is a metallo-proteinase with dipeptidyl-carboxypeptidase activity. Chymase (EC 3.4.21.39) which is a chymotrypsin-like enzyme expressed in the secretory granule of mast cells, catalyzes the production of angiotensin II in vascular tissues even when ACE is blocked (Figure 1). Chymase converts Ang I to Ang II with greater efficiency and selectivity than ACE [4]. Chymase converts precursors of transforming growth factor-β (TGF-β) and matrix metalloproteinase (MMP)-9 to their active forms contributing to vascular response to injury. Both TGF-β and MMP-9 are involved in tissue inflammation and fibrosis, resulting in organ damage [6]. Previous studies have demonstrated the involvement of chymase in the escalation of dermatitis and chronic inflammation pursuing cardiac and pulmonary fibrosis [7]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call